{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-052469","form_type":"8-K","ticker":"ONCO","cik":"0001782107","company_name":"Onconetix, Inc.","filed_at":"2024-06-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.069071+00:00","generated_at":"2026-06-01T04:39:15.087823+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Onconetix CFO Bruce Harmon resigns; Karina Fedasz appointed interim CFO","bullets":["Bruce Harmon resigned as CFO effective June 8, 2024; receives $66,152.61 severance under release agreement.","Karina M. Fedasz, 51, appointed Interim CFO effective June 10, 2024; CFO Squad LLC engaged for accounting services.","Fedasz previously served as CFO at IDW Media Holdings and Head of Business Development at Evofem Biosciences.","Compensation for Fedasz to be determined later; Harmon's unvested equity forfeited."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-052469","json":"https://secwatch.observer/filing/0001213900-24-052469.json","markdown":"https://secwatch.observer/filing/0001213900-24-052469.md","text":"https://secwatch.observer/filing/0001213900-24-052469.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782107/000121390024052469/0001213900-24-052469-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782107/000121390024052469/ea0207635-8k_onconetix.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:39:15.087823+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"657f5834f2","claim":"Karina M. Fedasz was appointed as Interim Chief Financial Officer at Onconetix, Inc..","evidence_excerpt":"On June 10, 2024, the Company appointed Karina M. Fedasz, 51, as Interim Chief Financial Officer of the Company, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390024052469/0001213900-24-052469-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"ded773d61f","claim":"Bruce Harmon resigned as Chief Financial Officer at Onconetix, Inc..","evidence_excerpt":"On June 8, 2024, Bruce Harmon resigned as Chief Financial Officer of Onconetix, Inc. (the “ Company ”), effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390024052469/0001213900-24-052469-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}